Klin Farmakol Farm. 2024;38(1):5-8 | DOI: 10.36290/far.2024.001

Betablockers and CV disease - controversy 2023

Jiří Vítovec1, 2, Monika ©pinarová1
1 I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
2 Ústav farmakologie a toxikologie Farmaceutické fakulty MU, Brno

Beta-blockers are used for a wide range of cardiovascular diseases (CVD) - from arterial hypertension to heart failure. Recently, however, a number of analyzes and information have appeared that question the role of beta-blockers in some indications. We provide an overview of the controversies that have arisen around beta-blockers in the treatment of heart failure, hypertension, arrhythmias, in the secondary prevention of ischemic heart disease, and in perioperative administration to patients during non-cardiac operations.

Keywords: beta blockers, heart failure, hypertension, arrhythmia, CHD, perioperative care.

Accepted: March 26, 2024; Published: April 8, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinarová M. Betablockers and CV disease - controversy 2023. Klin Farmakol Farm. 2024;38(1):5-8. doi: 10.36290/far.2024.001.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bhatt DL. Opie´s Cardiovascular Drugs A Companion to Braunwald´s Heart Disease 9th Ed. Saunders Elsevier 2021;696.
    2. Vítovec J, Kollár P, Lábr K. Betablokátory v léčbě kardiovaskulárních onemocnění. Grada Publishing, a. s., 2022;130.
    3. The BEST Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-1667. Go to original source... Go to PubMed...
    4. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Europ Heart J 2021;42:3599-3726.
    5. Swedberg K, Komajda M, Bohm M, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885. Go to original source... Go to PubMed...
    6. Lund LH, Benson L, Dahlstrom U, et al. Association Between Use of β-Blockers and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction. JAMA 2014;312:2008-2018. Go to original source... Go to PubMed...
    7. Kotecha D, Holmes J, Krum H, et al. on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet 2014;384:2235-2243. Go to original source... Go to PubMed...
    8. Fauchier L. Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure? Cardiac Failure Review, 2016;2(1):35-39. Go to original source... Go to PubMed...
    9. Allen LA, Fonarow GC, Simon DN, et al. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. J Am Coll Cardiol 2015;65: 2691-2698. Go to original source... Go to PubMed...
    10. Zelinka T. Postavení betablokátorů v léčbě hypertenze ve světle současných guidelines. Arteriální hypertenze - současné klinické trendy 2022;20:139-147.
    11. Widimsky J jr., Filipovsky J, Ceral J, et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2022. Hypertenze & KV prevence 2022;12 .
    12. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of arterial hypertension? A meta-analysis. Lancet 2005;366:1545-1553. Go to original source... Go to PubMed...
    13. Hradec J. Kontroverze kolem betablokátorů. Vnitřní Lek 2015;61:410-416.
    14. Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a metanalysis od randomized trials. Am J Med 2014;127:939-953. Go to original source... Go to PubMed...
    15. Kala P, Mates M, ®elízko M, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Cor Vasa 2017;59:e613-e644. Go to original source...
    16. Bangalore S, Steg PG, Deedwania P, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-1349. Go to original source... Go to PubMed...
    17. Danchin N, Laurent S. Are beta‑blockers truly helpful in patients with CAD? Nat. Rev. Cardio 2013;10:11-12. Go to original source... Go to PubMed...
    18. Steg PG, De Silva R. Beta-Blockers in Asymptomatic Coronary Artery Disease. No Benefit or No Evidence? J Am Col Cardiol 2014:64:253-255. Go to original source... Go to PubMed...
    19. Poldermans D, Bax JJ, Boersma E, et al. Guidelines for preoperative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30:2769-2812. Go to original source... Go to PubMed...
    20. Devereaux PJ, Yang H, Yusuf S, et al. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial). Lancet 2008; 371:1839-1847. Go to original source... Go to PubMed...
    21. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Europ Heart J 2022;43:3826-3924.
    22. Friedell ML, VanWay CW III, Freyberg RW, et al. Beta - Blockade and Operative Mortality in Noncardiac Surgery. Harmful or Helpful? JAMA Surg. 2015;150:658-663. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.